Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncoimmunology
المؤلفون الرئيسيون: Arra, Aditya, Pech, Maximilian, Fu, Hang, Lingel, Holger, Braun, Franziska, Beyer, Christian, Spiliopoulou, Myra, Bröker, Barbara M., Lampe, Karen, Arens, Christoph, Vogel, Katrin, Pierau, Mandy, Brunner-Weinzierl, Monika C.
التنسيق: Artigo
اللغة:Inglês
منشور في: Taylor & Francis 2021
الموضوعات:
Original Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC8204976/
https://ncbi.nlm.nih.gov/pubmed/34178430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1938475
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة